AHC Europe supports national AHC and ATP1A3 organisations, as well as patients and families. The organisation aims to ensure that no family in a European country without an official AHC organisation feels isolated.
Mission statement
Our mission is to bring together and support AHC and ATP1A3 families and to accelerate research that leads to effective treatments.
Our goals
- Establish a Strong and Sustainable European Patient Association
AHC Europe aims to be a visible, well-structured, and trusted European organisation that supports patients, families and national associations. - Support Patient Associations
Enable national AHC and ATP1A3 patient associations to learn from each other and improve their operations, so they can better support, educate and connect families. - Foster European and Global Collaboration
Strengthen collaboration among European AHC and ATP1A3 patient association and foster a unified European patient community to become a stronger, unified voice towards researchers, healthcare professionals, and external stakeholders. - Advocate for AHC & ATP1A3 Patients and Families
Represent and protect the interests, rights and needs of individuals living with AHC and ATP1A3-related diseases and their families across Europe and within European rare disease organisations and networks, such as EpiCare, EURORDIS, the IAHCRC and the ATP1A3 Symposium. - Promote and Accelerate Research
Advance and promote scientific research aimed at better understanding, treating, and ultimately curing AHC and ATP1A3 disorders. - Improve Patient Outcomes
Support the need for early and accurate diagnosis, appropriate care and effective treatment for all patients with AHC and ATP1A3 diseases.
* We recognise the need to also advocate for ATP1A3 diseases alongside AHC given this is the principal gene causing AHC in approx. 80% of cases.
